Gene · 6491
Papers1,377
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 1,377
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial. | Lancet Oncol | 2026 | 42636838 | PubTator, text mining | PubMed |
| Tumor-infiltrating lymphocytes density and distribution in breast cancer: A two-year study on their clinicopathological correlation. | J Cancer Res Ther | 2026 | 42617026 | PubTator, text mining | PubMed |
| Prognostic Value of Morphological Characteristics and Immune Microenvironment in High-Grade Serous Cancer (HGSC). | Cancers (Basel) | 2026 | 42512390 | PubTator, text mining | PubMed |
| Tertiary lymphoid structure-related genes drive tumor microenvironment heterogeneity and prognostic disparities in left- vs. right-sided colon cancer. | Transl Cancer Res | 2026 | 42180948 | PubTator, text mining | PubMed |
| Multi-omics analysis reveals the key role of STIL in Li-Fraumeni syndrome and osteosarcoma. | NPJ Precis Oncol | 2026 | 42009739 | PubTator, text mining | PubMed |
Level of estrogen receptor expression, histological grade, and computationally assessed stromal TILs on pre-treatment biopsies predict pathological complete response to neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer. | Virchows Arch | 2026 | 42008179 | PubTator, text mining | PubMed |
| Clinicopathological and molecular characteristics associated with pathological complete response in neoadjuvant immunotherapy for breast cancer. | Front Immunol | 2026 | 41972153 | PubTator, text mining | PubMed |
| Comparative Analysis of Stromal Tumor Infiltrating Lymphocytes in Various Grades and Molecular Subtypes of Breast Carcinoma. | Ann Afr Med | 2026 | 41943585 | PubTator, text mining | PubMed |
| [Clinical analysis of 7 cases of childhood acute lymphoblastic leukemia with PDGFRB rearrangement]. | Zhongguo Dang Dai Er Ke Za Zhi | 2026 | 41914417 | PubTator, text mining | PubMed |
| Identification of Key Genes via Integrated Multi-Omics and Machine Learning Uncovers Tumor Biological Features and Prognostic Biomarkers in Uterine Leiomyosarcoma. | Int J Med Sci | 2026 | 41799759 | PubTator, text mining | PubMed |
| Resonator-enhanced distributed Bragg reflector lasers. | Light Sci Appl | 2026 | 41771839 | PubTator, text mining | PubMed |
| Genomic Landscape of Poorly Differentiated Gastric Carcinoma: An AACR GENIE® Project. | Life (Basel) | 2026 | 41752847 | PubTator, text mining | PubMed |
| Disrupted STIL-BRCA1 axis causes centrosome amplification and genomic instability. | FEBS Lett | 2026 | 41749477 | PubTator, text mining | PubMed |
| Tumour microenvironment and HER2-low status dictate response and resistance to anthracycline-taxane chemotherapy in premenopausal TNBC: a retrospective multicohort study. | Front Pharmacol | 2026 | 41737551 | PubTator, text mining | PubMed |
| Adjuvant pegylated liposomal doxorubicin versus epirubicin sequential paclitaxel in triple-negative breast cancer: comparable efficacy with a distinct safety profile. | Front Immunol | 2026 | 41716408 | PubTator, text mining | PubMed |
| The γ-TuRC: mastermind of multipurpose actions at the centrosome. | Cell Mol Life Sci | 2026 | 41711931 | PubTator, text mining | PubMed |
| Diagnostic and immunological roles of leptin gene rs7799039 polymorphism and cytokines in COVID-19, HCV, and dual infection. | Sci Rep | 2026 | 41629381 | PubTator, text mining | PubMed |
| Role of tumor‑infiltrating lymphocytes and miR‑155 in breast cancer: Insights into carcinogenesis and their potential as prognostic biomarkers (Review). | Oncol Rep | 2026 | 41543151 | PubTator, text mining | PubMed |
| Personalized high-intensity temporal interference stimulation decouples cerebellar networks to enhance implicit learning. | J Neuroeng Rehabil | 2026 | 41484914 | PubTator, text mining | PubMed |
| Tumor Stroma Infiltrating T Cells Predict the Efficacy of Anti-CTLA-4 Antibody in NSCLC. | Anticancer Res | 2026 | 41469097 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6491/papers